NasdaqGS:KNSABiotechs
Kiniksa (KNSA) Is Up 6.2% After Analyst Upgrade And Institutional Buying Surge - What's Changed
Kiniksa Pharmaceuticals International was recently upgraded to a Zacks Rank #1 (Strong Buy) after analysts raised their earnings estimates on the back of robust quarterly revenue and net profit growth.
This upgrade has coincided with a very large increase in institutional ownership, suggesting that major investors are aligning behind the company’s improving fundamentals.
Next, we’ll explore how stronger earnings expectations and rising institutional backing may influence Kiniksa’s existing...